Jump to content

Clostridium butyricum

From Wikipedia, the free encyclopedia

Clostridium butyricum
C. butyricum MIYAIRI 588 tablets produced by Miyarisan Pharmaceutical, Tokyo, Japan.
Scientific classification Edit this classification
Domain: Bacteria
Phylum: Bacillota
Class: Clostridia
Order: Eubacteriales
Family: Clostridiaceae
Genus: Clostridium
Species:
C. butyricum
Binomial name
Clostridium butyricum
Prazmowski 1880 (Approved Lists 1980)

Clostridium butyricum is a strictly anaerobic endospore-forming Gram-positive butyric acid–producing bacillus subsisting by means of fermentation using an intracellularly accumulated amylopectin-like α-polyglucan (granulose) as a substrate. It is uncommonly reported as a human pathogen and is widely used as a probiotic in Japan, Korea, and China.[1] C. butyricum is a soil inhabitant in various parts of the world, has been cultured from the stool of healthy children and adults, and is common in soured milk and cheeses.[2] The connection with dairy products is shown by the name, the butyr- in butyricum reflects the relevance of butyric acid in the bacteria's metabolism and the connection with Latin butyrum and Greek βούτυρον, with word roots pertaining to butter and cheese.[3]

Industrial relevance

[edit]

The study of fermentation in the 19th century was of interest not only to basic science but also as applied science funded by companies in certain industries, principally winemaking and brewing, as a means to reduce risk of bad batches through greater understanding and control of the process. Thus, early microbiologists such as Louis Pasteur were funded in their research into microbial metabolism and biochemistry. Such research led to the first understanding of anaerobic metabolism,[3] and butyric acid fermentation was humans' initial window into that world.[3] In 1880, Adam Prażmowski from the University of Leipzig first assigned the binomial name Clostridium butyricum.[3][4]

Therapeutic uses

[edit]

The first C. butyricum MIYAIRI strain was isolated by Dr. Chikaji Miyairi from feces in Japan in 1933.[5] In 1963, CBM 588 was isolated from a soil sample in Nagano, Japan.[5] Preparations based on CBM 588 have a long history of safe use in human populations in Japan, where such products are variously classed as pharmaceutical drugs, "quasi drugs", and OTC (Over The Counter) probiotics. The safe therapeutic use of CBM 588 in humans populations is supported by various peer-reviewed publications and case studies, including reports of CBM 588 use in severely-ill, immunocompromised, and hospitalized patients, as well as in pregnant women.[6][7][8][9]

Its usefulness stems primarily from its ability to interfere with the growth of highly pathogenic Clostridioides difficile by antagonizing its multiplication.[10] It is often used in Japanese hospitals for C. difficile prophylaxis among in-patients and, particularly, during administration of certain powerful antibiotics (i.e. Levofloxacin) associated with opportunistic C. difficile infection.

CBM 588 was approved for clinical use in humans by the Japanese Ministry of Health and Welfare in 1970.[11] The standard preparation as marketed by Miyarisan Pharmaceutical (Tokyo, Japan) consists of white, marked tablets each containing 0.35 × 106 colony forming units (CFU) of C. butyricum MIYAIRI 588 (as active agent). CBM 588 does not establish permanently in the gut, in common with other orally administered probiotic bacteria. CBM 588 for clinical use is produced by submerged anaerobic fermentation followed by centrifugation, drying, blending and packaging.[9]

The MIYAIRI 588 strain of C. butyricum does not carry any genes encoding any toxins and virulence factors associated with Clostridium or other enteropathogens.[12] Absence of neurotoxin production has been demonstrated by polymerase chain reaction (PCR) and Southern blot hybridisation for type E botulinum toxin gene. The absence of genes encoding botulinum neurotoxin A,B,F and genes encoding non-toxic haemagglutinin (NTNH) and genes encoding Clostridium perfringens toxins (alpha, beta, epsilon and iota) has been demonstrated by PCR assay.

This strain is deposited at the Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under the strain name Clostridium butyricum MIYAIRI 588 strain, deposit number FERM BP-2789. Recent European Food Safety Authority opinions confirm the official strain nomenclature as Clostridium butyricum FERM BP-2789.

In addition, other C. butyricum strains have been discovered, including RH2,[13] S-45-5,[14] UBCB 70,[15] and CGMCC0313,[16] and used in different fields.

References

[edit]
  1. ^ Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. (February 2003). "Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI". Pediatrics International. 45 (1): 86–90. doi:10.1046/j.1442-200x.2003.01671.x. PMID 12654076. S2CID 23451154.
  2. ^ Meng X, Karasawa T, Zou K, Kuang X, Wang X, Lu C, et al. (August 1997). "Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism". Journal of Clinical Microbiology. 35 (8): 2160–2162. doi:10.1128/JCM.35.8.2160-2162.1997. PMC 229926. PMID 9230405.
  3. ^ a b c d Newman G (1904). Bacteriology And The Public Health. Philadelphia, Pennsylvania: P. Blakiston's Son and Co. pp. 107–110. ISBN 9781345750270.
  4. ^ Skerman VB, McGowan V, Sneath PH (1980). "Approved Lists of Bacterial Names". International Journal of Systematic and Evolutionary Microbiology. 30 (1): 225–420. doi:10.1099/00207713-30-1-225. ISSN 1466-5034.
  5. ^ a b Ariyoshi T, Hagihara M, Takahashi M, Mikamo H (February 2022). "Effect of Clostridium butyricum on Gastrointestinal Infections". Biomedicines. 10 (2): 483. doi:10.3390/biomedicines10020483. PMC 8962260. PMID 35203691.
  6. ^ Ito I, Hayashi T, Iguchi A, Endo H, Nakao M, Kato S, et al. (April 1997). "[Effects of administration of Clostridium butyricum to patients receiving long-term tube feeding]" [Effect of butyric acid bacteria suspension on intestinal mucosal function in elderly patients undergoing tube feeding]. Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics (in Japanese). 34 (4): 298–304. doi:10.3143/geriatrics.34.298. PMID 9212685.
  7. ^ Seki H, Shiohara M, Matsumura T, Miyagawa N, Tanaka M, Komiyama A, et al. (February 2003). "Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI". Pediatrics International. 45 (1): 86–90. doi:10.1046/j.1442-200X.2003.01671.x. PMID 12654076. S2CID 23451154.
  8. ^ Maebashi M, Sato T, Makino Y, Furukawa Y, Inomata T (1998). "Implication of 'Harmful' Intestinal Microflora in the Pathogenesis of Diseases with Immune Dysfunction". Bioscience and Microflora. 17 (1): 55–60. doi:10.12938/bifidus1996.17.55. S2CID 54698273.
  9. ^ a b Miyarisan Pharmaceutical Co Ltd (31 January 2012). Public Version - Clostridium butyricum MIYAIRI 588 as a novel food supplement (PDF) (Report). Advisory Committee on Novel Foods and Processes. Retrieved 2 January 2024.
  10. ^ Woo TD, Oka K, Takahashi M, Hojo F, Osaki T, Hanawa T, et al. (November 2011). "Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain". Journal of Medical Microbiology. 60 (Pt 11): 1617–1625. doi:10.1099/jmm.0.033423-0. PMID 21700738.
  11. ^ Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, et al. (December 2005). "Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy". World Journal of Gastroenterology. 11 (47): 7520–7524. doi:10.3748/wjg.v11.i47.7520. PMC 4725182. PMID 16437727.
  12. ^ "Committee Paper for Discussion: Adivosry Committee for Novel Foods and Processes - Clostridium Butyricum Probtiotic" (PDF). Archived from the original (PDF) on 3 November 2013. Retrieved 8 September 2013.
  13. ^ Li Y, Liu M, Liu H, Sui X, Liu Y, Wei X, et al. (25 March 2021). "The Anti-Inflammatory Effect and Mucosal Barrier Protection of Clostridium butyricum RH2 in Ceftriaxone-Induced Intestinal Dysbacteriosis". Frontiers in Cellular and Infection Microbiology. 11: 647048. doi:10.3389/fcimb.2021.647048. PMC 8027357. PMID 33842393.
  14. ^ Chathuranga K, Shin Y, Uddin MB, Paek J, Chathuranga WA, Seong Y, et al. (10 October 2023). "The novel immunobiotic Clostridium butyricum S-45-5 displays broad-spectrum antiviral activity in vitro and in vivo by inducing immune modulation". Frontiers in Immunology. 14: 1242183. doi:10.3389/fimmu.2023.1242183. PMC 10595006. PMID 37881429.
  15. ^ Sulthana A, Thorramamidi A, Lakshmi SG, Madempudi RS (January 2019). "Whole-Genome Shotgun Sequencing and Characterization of Probiotic Strain Clostridium butyricum UBCB 70 To Assess Its Safety". Microbiology Resource Announcements. 8 (5): e01732–18. doi:10.1128/MRA.01732-18. PMC 6357650. PMID 30714044.
  16. ^ Juan Z, Zhao-Ling S, Ming-Hua Z, Chun W, Hai-Xia W, Meng-Yun L, et al. (July 2017). "Oral administration of Clostridium butyricum CGMCC0313-1 reduces ovalbumin-induced allergic airway inflammation in mice". Respirology. 22 (5): 898–904. doi:10.1111/resp.12985. PMID 28122397.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Clostridium_butyricum&oldid=1252006770"